Xevinapant hydrochloride
Xevinapant (AT-406) hydrochloride 是一种有效的、口服生物可利用的 Smac 模拟物，也是细胞凋亡蛋白 (IAPs) 抑制剂的拮抗剂。Xevinapant hydrochloride 与 XIAP、cIAP1 和 cIAP2 蛋白结合，Ki 分别为 66.4、1.9 和 5.1 nM。Xevinapant hydrochloride 在无细胞功能测定中有效拮抗 XIAP BIR3 蛋白，诱导细胞 cIAP1 蛋白的快速降解，并抑制各种人类癌细胞系中的癌细胞生长。Xevina
此产品仅用于科学研究，我们不为任何个人用途提供产品和服务
-
包装价格促销价数量
-
10mg￥1625.001300.00- +
-
50mg￥7012.005610.00- +
- 货号: ajcx35390
- CAS: 1071992-57-8
- 别名: AT-406 hydrochloride; Debio 1143 hydrochloride; SM-406 hydrochloride
- 分子式: C32H44ClN5O4
- 分子量: 598.18
- 纯度: ＞98%
- 溶解度: DMSO : 175 mg/mL (292.55 mM; Need ultrasonic)
- 储存: Store at -20°C, sealed storage, away from moisture and light
- 库存: 现货
Background
Xevinapant (AT-406) hydrochloride is a potent and orally bioavailable Smac mimetic and an antagonist of the inhibitor of apoptosis proteins (IAPs). Xevinapant hydrochloride binds to XIAP, cIAP1, and cIAP2 proteins with Kis of 66.4, 1.9, and 5.1 nM, respectively. Xevinapant hydrochloride effectively antagonizes XIAP BIR3 protein in a cell-free functional assay, induces rapid degradation of cellular cIAP1 protein, and inhibits cancer cell growth in various human cancer cell lines. Xevinapant hydrochloride is highly effective in induction of apoptosis in xenograft tumors[1][2].
Xevinapant (AT-406) hydrochloride potently inhibits cell growth in the MDA-MB-231 breast and SK-OV-3 ovarian cancer cell lines with IC50=144 nM and 142 nM, respectively.Xevinapant (0-3 μM; 0-48 horus) hydrochloride effectively induces cell death in a time- and dose-dependent manner[1].
Xevinapant (AT-406) hydrochloride is very effective in inhibition of tumor growth in the MDA-MB-231 xenograft model, and has minimal toxicity to animals[1]. Xevinapant hydrochloride evaluated for its pharmacokinetic (PK) properties in mice, rats, non-human primates and dogs[1].
[1]. Cai Q, Sun H, Peng Y, et al. A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment. J Med Chem. 2011;54(8):2714-2726.
[2]. Brunckhorst MK, et al. AT-406, an orally active antagonist of multiple inhibitor of apoptosis proteins, inhibits progression of human ovarian cancer. Cancer Biol Ther. 2012;13(9):804-811.
